Quick Answer
Amphastar Pharmaceuticals, Inc. reported Research And Development Expense of $85.84 million for the year ending 2025.
- Amphastar Pharmaceuticals, Inc. showed an increase of +16.1% in Research And Development Expense from 2024 to 2025.
- This data is from Amphastar Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), Amphastar Pharmaceuticals, Inc.'s Research And Development Expense has grown by 175.5%.
- Historical annual values: Fiscal year 2025: $85.84 million | Fiscal year 2024: $73.91 million | Fiscal year 2023: $73.74 million | Fiscal year 2022: $74.77 million | Fiscal year 2021: $60.93 million | Fiscal year 2020: $67.23 million | Fiscal year 2019: $68.85 million | Fiscal year 2018: $57.56 million | Fiscal year 2017: $43.50 million | Fiscal year 2016: $41.52 million | Fiscal year 2015: $37.27 million | Fiscal year 2014: $28.87 million | Fiscal year 2013: $33.02 million | Fiscal year 2012: $31.16 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: